Positive associations between galectin-3 and PSA levels in prostate cancer patients: A prospective clinical study-I

Oncotarget

Volumn 7, Issue 50, 2016, Pages 82266-82272

  Nakajima, Kosei ^a   Heilbrun, Lance K ^a,b   Hogan, Victor ^a   Smith, Daryn ^a,b   Heath, Elisabeth ^a   Raz, Avraham ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Autoantibody; Diagnostic biomarker; Galectin 3; Prostate cancer; PSA

Indexed keywords

AUTOANTIBODY; GALECTIN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; GALECTIN-3, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; ARTICLE; CANCER PATIENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PILOT STUDY; PROSPECTIVE STUDY; PROSTATE CANCER; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNOLOGY; LEAST SQUARE ANALYSIS; MICHIGAN; PATHOLOGY; PREDICTIVE VALUE; PROSTATE TUMOR; REPRODUCIBILITY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

AUTOANTIBODIES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GALECTIN 3; HUMANS; IMMUNITY, HUMORAL; KALLIKREINS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MALE; MICHIGAN; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85003846674     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12619     Document Type: Article

References (16)

1. Moyer VA. US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157(2):120-134.
2. Nakajima K, Heilbrun L, Smith D, Hogan V, Raz A and Heath A. The influence of PSA autoantibodies in prostate cancer patients: A prospective clinical study-II. Oncotarget. 2016; doi: 10.18632/oncotarget.12620.
3. Harazono Y, Kho DH, Balan V, Nakajima K, Hogan V and Raz A. Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling. Oncotarget. 2015; 6(23):19592-19604. doi:10.18632/oncotarget.4285.
4. Balan V, Nangia-Makker P, Kho DH, Wang Y and Raz A. Tyrosine-phosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage. J Biol Chem. 2012; 287(8):5192-5198.
5. Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, Donat TL, Tait L, Hogan V and Raz A. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 1995; 87(5):348-353.
6. Glinskii OV, Sud S, Mossine VV, Mawhinney TP, Anthony DC, Glinsky GV, Pienta KJ and Glinsky VV. Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine. Neoplasia. 2012; 14(1):65-73.
7. Nakajima K, Kho DH, Yanagawa T, Harazono Y, Gao X, Hogan V and Raz A. Galectin-3 inhibits osteoblast differentiation through notch signaling. Neoplasia. 2014; 16(11):939-949.
8. Nakajima K, Kho DH, Yanagawa T, Harazono Y, Hogan V, Chen W, Ali FR, Mehra R and Raz A. Galectin-3 cleavage alters bone remodeling: Different outcomes in breast and prostate cancer skeletal metastasis. Cancer Res. 2016 76(6):1391-1402.
9. Nakajima K, Kho DH, Yanagawa T, Zimel M, Heath E, Hogan V and Raz A. Galectin-3 in bone tumor microenvironment: A beacon for individual skeletal metastasis management. Cancer Metastasis Rev. 2016; 35(2):333-346.
10. Balan V, Wang Y, Nangia-Makker P, Kho DH, Bajaj M, Smith D, Heilbrun L, Raz A and Heath E. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 2013; 4(4):542-529. doi:10.18632/oncotarget.923.
11. Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT and Denmeade SR. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate. 2011; 71(15):1595-1607.
12. De Marzo AM, Nelson WG, Bieberich CJ and Yegnasubramanian S. Prostate cancer: New answers prompt new questions regarding cell of origin. Nat Rev Urol. 2010; 7(12):650-652.
13. Wang Y, Balan V, Gao X, Reddy PG, Kho D, Tait L and Raz A. The significance of galectin-3 as a new basal cell marker in prostate cancer. Cell Death Dis. 2013; 4:e753.
14. Johnson JL, Ellis BA, Noack D, Seabra MC and Catz SD. The Rab27a-binding protein, JFC1, regulates androgendependent secretion of prostate-specific antigen and prostatic-specific acid phosphatase. Biochem J. 2005; 391(Pt3):699-710.
15. Nicotera TM, Schuster DP, Bourhim M, Chadha K, Klaich G and Corral DA. Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells. Prostate. 2009; 69(12):1270-1280.
16. Hintze J. Power and Sample Size (PASS) 11. NCSS, LLC Kaycville, Utah, USA. 2011; www.ncss.com.